AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 261 min read$RCKT

Shah Gaurav sold $172K of RCKT

Shah Gaurav (CEO) sold 55,684 shares of ROCKET PHARMACEUTICALS, INC. (RCKT) at $3.09 ($0.17M total) on 2026-05-21.

Original reporting
SEC EDGAR · Shah Gaurav
Published May 26, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 26, 2026, 11:51 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RCKT
Neutral
medium confidence
Mentioned
$RCKT
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RCKTNeutralLow
01

Why it matters

The disclosure may slightly weigh on sentiment for RCKT traders, but it does not introduce new operational, clinical, or financial information.

02

Market read

Traders may monitor for follow-on insider activity, but the filing alone is unlikely to drive a sustained repricing.

03

What to watch

No context on prior sales cadence, total insider ownership trend, or whether the sale was part of broader personal financial planning.

Relevance 6/10Timing: Immediate (same-day read-through for sentiment), but not a catalyst for fundamentals.

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Rocket Pharmaceuticals (RCKT).

Company-level read

Ticker impact

$RCKTNeutralMedium confidence
Context

Rocket Pharmaceuticals CEO Shah Gaurav sold 55,684 shares in an open-market transaction reported on SEC Form 4.

Expected impact

Likely limited, short-lived impact unless follow-on selling accelerates or coincides with other negative news.

Evidence & confidence

This is a routine Form 4 disclosure (no 10b5-1 plan stated) with a modest dollar amount relative to typical market moves; without accompanying company-specific news, directional conviction is low.

Market effects

Sector

Minimal—single-company insider transaction without sector-wide regulatory/clinical developments.

Regional

None indicated; filing is US-based and company-specific.

Global

Low—no international deal, trial, or regulatory action referenced.

Counterpoint

What could challenge this read

The sale could be liquidity-driven (taxes/diversification) and does not necessarily reflect negative expectations.

Key entities

  • issuer
    Rocket Pharmaceuticals, Inc.

    Subject of the Form 4 insider sale by CEO Shah Gaurav.

  • insider
    Shah Gaurav

    CEO who sold 55,684 shares at $3.0860/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RCKT insider trading history →

Related articles

SEP 23
$RCKTHighAI 8/10

Rocket Pharmaceuticals (RCKT) Gets FDA Alignment on Heart Drug Trial. Can it Ease Safety Concerns?

Rocket Pharmaceuticals (RCKT) announced FDA agreement to include 3 patients in its Phase 2 trial for Danon disease gene therapy RP-A501, with 9 more to be enrolled. The modified protocol includes dose adjustments and enhanced safety monitoring. The FDA confirmed 12-month co-primary endpoints for efficacy. The trial aims to complete dosing by mid-2027, with primary assessment 12 months post-treatment. Safety and efficacy data remain key uncertainties.

insidermonkey.com2 min
SEP 17
$RCKTMed

Refinancing all but vanishes as mortgage rates climb

Major U.S. mortgage lenders adjusted their 30-year fixed rates following the Federal Reserve's rate hike. Rocket Mortgage and Bank of America increased rates, while U.S. Bank lowered its. Freddie Mac reported a national average rate of 6.76%, with refinance applications dropping 9% week-over-week. Home-equity products saw increased interest, and the NAHB/Wells Fargo Housing Market Index fell to 32 in September.

aol.com3 min
SEP 16
$UNPMed

This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Ulta Beauty (NASDAQ:ULT

Analysts upgraded several companies: Needham upgraded Similarweb (SMWB) to Buy with a $11 target, Wolfe Research upgraded Paychex (PAYX) to Peer Perform, Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 target, UBS upgraded Union Pacific (UNP) to Buy with a $339 target, and Barclays upgraded Alvotech (ALVO) to Overweight with a $8 target.

benzinga.com2 min
SEP 16
$RCKTHighAI 8/10

Rocket Pharmaceuticals’ FDA Decision Clears ‘Meaningful Regulatory Overhang,’ Says Needham — Sees 150% Upside Potential In RCKT Stock

Rocket Pharmaceuticals (RCKT) received an FDA alignment on a pivotal study for its genetic disease therapy, leading to a 'Buy' upgrade from Needham with a $9 price target, implying 150% upside. The FDA confirmed continued enrollment in the Phase 2 study of RP-A501 for Danon Disease, with dosing expected to complete by mid-2027. The stock was up 7.6% on the news.

stocktwits.com2 min
SEP 16
$RCKTHighAI 8/10

Needham Upgrades Rocket Pharmaceuticals (RCKT) to Buy After FDA

Needham upgraded Rocket Pharmaceuticals (RCKT) to Buy with a $9 price target after FDA approved the trial design for RP-A501, a gene therapy for Danon Disease. The FDA's modifications include dosing and patient inclusion criteria. RCKT has no revenue, a $375M market cap, and a GF Score of 25, indicating financial stability but operational challenges. Insiders sold $1.0M in shares over the past year, while institutional guru ownership remains steady.

gurufocus.com2 min